Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer, Sarcoma
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma.
- Trial name
- NCT00003778
- Testing
- dolastatin 10
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with recurrent or resistant epithelial ovarian cancer.
- Trial name
- NCT00400348
- Testing
- Panzem Nanocrystal Colloidal Dispersion (NCD)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- CASI pharmaceuticals, Inc.
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
- Trial name
- KOV-02S (NCT07171528)
- Testing
- Secondary Cytoreductive Surgery
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- National Cancer Center, Korea
Recurrent Ovarian Cancer
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
The purpose of this study is to find out if a new drug, LDE225, is safe and has beneficial effects when combined with paclitaxel in women with platinum resistant ovarian cancer.
- Trial name
- NCT02195973
- Testing
- LDE225
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT04999605
- Testing
- AK112 low dose, AK112 medium dose, AK112 high dose
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Akeso
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Carcinoma
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
Most studies performing hyperthermic intraoperative intraperitoneal chemotherapy dose the cytotoxic drugs according to the body surface (like 50 mg/m² cisplatin) in analogy to systemic, intravenous chemotherapy (usually using the…
- Trial name
- NCT00968799
- Testing
- Hyperthermic intraoperative intraperitoneal chemotherapy, Cytoreduction, Cisplatin
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Cantonal Hospital of St. Gallen
Adult Solid Tumor
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
The purpose of this study is to test the CANscript™ sensitivity assay, which is a new and different assay developed to test the sensitivity of different cancer types to physician selected therapies (both drugs and/or drug…
- Trial name
- ANCERS-2 (NCT03253575)
- Testing
- CANscript
- Where
- 30 sites in United States
- Volunteers
- 800 people
- Sponsor
- Mitra RxDx, Inc.
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Carcinoma, Renal Cancer
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE)…
- Conditions
- Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- PELFIRE (NCT07782164)
- Testing
- Irreversible electroporation
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- Amsterdam UMC, location VUmc
Platinum-resistant Recurrent Ovarian Cancer
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT04720807
- Testing
- Letrozole combined with anlotinib hydrochloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Extragonadal Germ Cell Tumor, Ovarian Cancer
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients with recurrent or…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002903
- Testing
- docetaxel
- Where
- 49 sites in Austria, Belgium and 12 more
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Ovarian Cancer
Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer
Based on these pre-clinical data, which were generated by our group, the investigators propose to test in a phase I/II clinical trial the following hypothesis: demethylation induced by decitabine results in re-sensitization to…
- Trial name
- NCT00477386
- Testing
- decitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Indiana University
Ovarian Cancer
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.
Increasing number of ovarian cancer patients are receiving PARP inhibitor as maintenance or salvage therapy. Predictive factors to PARP inhibitor other than BRCA mutation or HRD status as well as specific resistance mechanism are…
- Trial name
- NCT05458973
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Yonsei University
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT05236686
- Testing
- Hepato-celiac lymphadenectomy
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Solid Tumors, Advanced Triple Negative Breast Cancer
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
This is a Phase 1b/2a dose escalation and expansion, multi-center study to be conducted in 2 phases: Phase 1b Dose Escalation Part 1 (Doublet Therapy) Dose Escalation Part 2 (Triplet Therapy) Phase 2a Dose Expansion (Triplet…
- Conditions
- Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer
- Trial name
- NCT03861403
- Testing
- TRX518, Cyclophosphamide, Avelumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Ovarian Cancer
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Patients with recurrent ovarian cancer will undergo resection of a safely accessible metastatic lesion, from which tumor-infiltrating lymphocytes (TIL) will be cultured, metabolically reprogrammed for metabolic fit T cells, then…
- Trial name
- OVAFIT-TIL (NCT07720180)
- Testing
- Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.